Hemolytic uremic syndrome atypical after kidney transplantation: a case report and literature review
PDF (Español (España))
PDF
HTML (Español (España))

How to Cite

1.
Ramírez JI, Gómez ED, Aldana Campos MC, Puerto R, Córdoba JP. Hemolytic uremic syndrome atypical after kidney transplantation: a case report and literature review. Rev. Colomb. Nefrol. [Internet]. 2017 Jan. 1 [cited 2022 Aug. 13];4(1):74-8. Available from: https://revistanefrologia.org/index.php/rcn/article/view/267

Abstract

Haemolytic uremic syndrome (HUS) is a clinical entity characterized by the appearance of non immune hemolytic anemia, thrombocytopenia and acute renal failure. It is a disease belonging to the group of thrombotic microangiopathy (MAT) which are part of thrombotic thrombocytopenic purpura also (PTT) and some other MAT associated with other medical conditions formerly known as secondary MAT.
Moreover, the variety known as atypical HUS (aHUS) is an ultra-orphan disease that frequently progresses to chronic renal failure (CRF) and is associated with high morbidity and mortality if not properly treated. If a patient presents its first clinical manifestation of aHUS later receive a cadaveric renal transplant which not only makes it an even more exotic case but involves more complexity in their management is presented.

https://doi.org/10.22265/acnef.4.1.267
PDF (Español (España))
PDF
HTML (Español (España))

References

1. George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost [Internet]. 2013 [accedido 01 Jan 2000];39(2):153–60. Available from: http://dx.doi.org/10.1055/s-0032-1333538. Mayo 2016.

2. Polito MG, Kirsztajn GM. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. J Bras Nefrol [Internet]. 2010 [accedido 01 Jan 2000];32(3):303–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21103695\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21103695. Mayo 2016.

3. Campistol Plana JM, Arias M, Ariceta Iraola G, Blasco M, Espinosa M, Grinyo JM, et al. Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Nefrología (Madr.) [Internet]. 2013 [accedido 01 Jan 2000];33:27–45.
Available from: http://dx.doi.org/10.3265Nefrologia.pre2012.Nov.11781

4. Cordoba JP, Mariel K, Carolina C, Espitaleta Z, Gonzalez E, Ibarra M, et al. Síndrome hemolítico urémico atípico, revisión de la literatura y documento de consenso: enfoque diagnóstico y tratamiento.Rev Colomb Nefrol. 2015;2(1):19–40.

5. Kavanagh D, Goodship THJ. Atypical hemolytic uremic syndrome. Curr Opin Hematol. 2010;17(5):432–8.

6. Zipfel PF, Wolf G, Jhon U, Kentouche K, and Skerka C. Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura? Pediatr Nephrol. 2011;26: 1947-56.

7. Ali M, Syed A, Bhandari S. Case series: hemolytic uremic syndrome another cause of transplant dysfunction. Transplant Proc [Internet]. 2013 [accedido 01 Jan 2000];45(9):3284–8.
Available from:http://dx.doi.org/10.1016/j.transproceed.2013.07.060

8. Hirt-Minkowski P, Dickenmann M, Schifferli JA. Atypical Hemolytic Uremic Syndrome: Update on the Complement System and What Is New. Nephron Clin Pract [Internet]. 2010 [accedido 01 Jan2000];114(4):c219–35.
Available from: http://dx.doi.org/10.1159/000276545

9. Laurence J. Atypical Hemolytic Uremic Syndrome ( aHUS ): making the diagnosis. Clin Adv Hematol Oncol [Internet]. 2012 Oct [accedido 01 Jan 2000]; 10 (10 Suppl 17):1-12.
Available from: https://www.ncbi.nlm.nih.gov/pubmed/23187605

10. Kreuter J, Winters JL. Drug-associated thrombotic microangiopathies. Semin Thromb Hemost [Internet]. 2012 [accedido 01 Jan 2000];38(8):839–44.
Available from: http://dx.doi.org/10.1055/s-0032-1328886

11. Vega J, Parodi C, Mendez GP, Goecke H. Síndrome hemolítico-urémico asociado al uso de gemcitabina. Rev Med Chil. 2013;141(6):797–802.

12. Fakhouri F, Fremeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med [Internet]. 2013 [accedido 01 Jan 2000];24(6):492–5. Available from: http://dx.doi.org/10.1016/j.ejim.2013.05.008

13. de Cordoba SR, Montes T. Síndrome hemolítico urémico atípico. Nefrol Supl Extraordin. 2011;2(1):58–65.

14. Joseph C, Gattineni J. Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr [Internet]. 2013 Apr [accedido 01 Jan 2000];25(2):209–15.
Available from: http://dx.doi.org/10.1097/MOP.0b013e32835df48a

15. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. N Engl J Med [Internet]. 2013 [accedido 01 Jan 2000];368(23):2169–81.
Available from: http://dx.doi.org/10.1056/NEJMoa1208981

16. Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open [Internet]. 2013 [accedido 01 Jan 2000];3(11): e003573.
Available from: http://dx.doi.org/10.1136/bmjopen-2013-003573

17. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis [Internet]. 2011 [accedido 01 Jan 2000];6(1):60. Available from: http://dx.doi.org/10.1186/1750-1172-6-60

18. Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol [Internet]. 2010 [accedido 01 Jan 2000];25(12):2431–42. Available from: http://dx.doi.org/10.1007s00467-010-1555-5

19. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood [Internet]. 2010 [accedido 01 Jan 2000];115(8):1500-11.
Available from http://dx.doi.org/10.1182/blood-2009-09-243790

20. Keating GM. Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome. Drugs [Internet]. 2013 [accedido en 01 Jan 2000];73(18):2053–66.
Available from: http://dx.doi.org/10.1007/s40265-013-0147-7

21. Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int [Internet]. 2015 [accedido 01 Jan 2000]; 87(5):1061-1073.
Available from: http://dx.doi.org/10.1038/ki.2014.423

22. Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol [Internet]. 2013 [accedido 01 Jan 2000];162(1):62–73.
Available from: http://dx.doi.org/10.1111/bjh.12347

23. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol [Internet]. 2007 [accedido 01 Jan 2000];25(11):1256–64.
Available from: http://dx.doi.org/10.1038/nbt1344

24. Hillmen P. The role of complement inhibition in PNH. Hematology [Internet]. 2008 [accedido 01 Jan 2000];2008(1):116–23.
Available from: https://doi.org/10.1182/asheducation-2008.1.116

25. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher M A, Niaudet P, Guest G, et al. Differential Impact of Complement Mutations on Clinical Characteristics in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol [Internet]. 2007 [accedido 01 Jan 2000];18(8):2392–400. Available from: https://doi.org/10.1681/ASN.2006080811

26. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS : the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood [Internet]. 2006 [accedido 01 Jan 2000];108(4):1267–79.
Available from: https://doi.org/10.1182/blood-2005-10-007252.
No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.

Dimensions


PlumX


Downloads

Download data is not yet available.